Impact of Chemo-induced Menopause on Quality of Life in Women <45 Years Old, Diagnosed With Non-metastatic Breast Cancer

Inclusion Criteria: * Patient aged over 18 and under 45 * Patient without amenorrhea at diagnosis * Performance status less than 2 (according to WHO criteria ) * Patient diagnosed with histologically proven non-metastatic breast cancer * Clinical Stages I, IIA, IIB and IIIA * Positive Hormone Receptors (defined by a rate of 10% of labeled cells and immunohistochemistry (IHC) ) or negative * Positive or negative HER2 status ( defined a score of 0 or 1 + by IHC , or a 2 + score by IHC and FISH / ISHS / CISH negative) * Patients to be treated with neoadjuvant or adjuvant chemotherapy * Satisfying hematological, renal and hepatic functions : PNN\> 2,109 / L, platelets \> 100 . 109 / L, Hb\> 10 g / dl , normal bilirubin, AST and ALT \<2.5 upper normal value ( VNS) , alkaline phosphatase \<2.5 VSN , creatinine clearance \> 60 ml / min * Obtaining informed consent in writing, signed and dated * Affiliation to Social Security system (or being the beneficiary of such a plan) under the terms of the Act of August 9, 2004 Exclusion Criteria: * Male patient * Metastatic cancer * Any T4 tumor (skin invasion, deep grip, inflammatory breast cancer) * Patient who underwent surgical castration of ovariectomy or hysterectomy or tubal ligation * Patients with endometriosis * Pregnant or breastfeeding patients * Patients with no effective contraception * Patients who have had hormone therapy or chemotherapy * Patient who have already taken Gn-RH or LH-RH analogues (chemical castration) * Patient whose mother was in menopause early without treatment * Presence of comorbidities related to fertility or medical history related to ovarian failure or sterility * Significant neurological or psychiatric abnormalities * Inability of the patient to complete the questionnaires (the language barrier) * Patients deprived of liberty by court or administrative decision * Patient with another pathology deemed incompatible with the inclusion of the patient in the protocol * Participation in another clinical trial involving the chemical or surgical castration of the patient * Patients geographically unstable in the 6 months following inclusion or residing away from the treatment center and thereby making it difficult to monitor